Easywell Biomedical

Easywell Biomedical is a global biopharmaceutical and medical device company headquartered in Hsinchu, Taiwan, with significant operations in the United States and China. Founded in 1998, the company has evolved through strategic acquisitions, including Magnifica and Transwell Biotech, to establish three core business sectors: pharmaceuticals, regenerative medicine, and medical devices. Its pharmaceutical division, primarily operating through its subsidiary Tulex Pharmaceuticals, focuses on developing technically challenging generics and 505(b)(2) specialty drugs using proprietary drug delivery platforms like BEST and GREAT. The company's portfolio includes FDA-approved treatments for depression, epilepsy, and overactive bladder, as well as a regenerative medicine pipeline targeting wound healing and Parkinson's disease. Easywell is publicly traded on the Taipei Exchange and maintains cGMP-compliant manufacturing facilities for both medical devices and pharmaceutical dosage forms.